PE20230780A1 - Compuestos utiles para inhibir la quinasa ret - Google Patents

Compuestos utiles para inhibir la quinasa ret

Info

Publication number
PE20230780A1
PE20230780A1 PE2022002489A PE2022002489A PE20230780A1 PE 20230780 A1 PE20230780 A1 PE 20230780A1 PE 2022002489 A PE2022002489 A PE 2022002489A PE 2022002489 A PE2022002489 A PE 2022002489A PE 20230780 A1 PE20230780 A1 PE 20230780A1
Authority
PE
Peru
Prior art keywords
carboxamide
amino
useful compounds
ret kinase
compounds
Prior art date
Application number
PE2022002489A
Other languages
English (en)
Inventor
Erin D Anderson
Steven W Andrews
Kevin R Condroski
Thomas C Irvin
Gabrielle R Kolakowski
Manoj Kumar
Elizabeth A Mcfaddin
Megan L Mckenney
Michael J Munchhof
michael b Welch
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20230780A1 publication Critical patent/PE20230780A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 5-AMINO-1-PIRAZOL-4-CARBOXAMIDA DE FORMULA (I) DONDE R1, R2, X1, X2, X3, X4, n Y EL ANILLO A SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: 5-AMINO-3-[4-(1-[[3-(2,2-DIMETILPROPIL)-1,2-OXAZOL-5-IL]CARBAMOIL]ETIL)FENIL]-1-ISOPROPILPIRAZOL-4-CARBOXAMIDA; 5-AMINO-3-[4-[1-[[5-(2,2-DIMETILPROPIL)-1,2-OXAZOL-3-IL]CARBAMOIL]ETIL]FENIL]-1-(1-METILCICLOPROPIL)-PIRAZOL-4-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA DE REORDENAMIENTO DURANTE LA TRANSFECCION (RET) SIENDO UTILES EN EL TRATAMIENTO DE CANCER ASOCIADO A RET, COMO EL CANCER DE PULMON, CANCER DE TIROIDES, NEOPLASIAS DE LAS GLANDULAS ENDOCRINAS.
PE2022002489A 2020-04-27 2021-04-23 Compuestos utiles para inhibir la quinasa ret PE20230780A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063015933P 2020-04-27 2020-04-27
PCT/US2021/028836 WO2021222017A1 (en) 2020-04-27 2021-04-23 Compounds useful for inhibiting ret kinase

Publications (1)

Publication Number Publication Date
PE20230780A1 true PE20230780A1 (es) 2023-05-09

Family

ID=75914595

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002489A PE20230780A1 (es) 2020-04-27 2021-04-23 Compuestos utiles para inhibir la quinasa ret

Country Status (18)

Country Link
US (2) US11613533B2 (es)
EP (1) EP4143184A1 (es)
JP (1) JP7441972B2 (es)
KR (1) KR20230005301A (es)
CN (1) CN115667253A (es)
AR (1) AR121914A1 (es)
AU (1) AU2021263541B2 (es)
BR (1) BR112022021735A2 (es)
CA (1) CA3177080A1 (es)
CL (1) CL2022003000A1 (es)
CO (1) CO2022016013A2 (es)
DO (1) DOP2022000234A (es)
EC (1) ECSP22083926A (es)
IL (1) IL297551B2 (es)
MX (1) MX2022013482A (es)
PE (1) PE20230780A1 (es)
TW (1) TWI777509B (es)
WO (1) WO2021222017A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3197032A1 (en) 2020-11-06 2022-05-12 Eli Lilly And Company Pyrazole derivatives as ret kinase inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
UA115264C2 (uk) * 2013-03-15 2017-10-10 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Піридинові похідні як інгібітори реаранжованої у процесі трансфекції (ret) кінази
WO2017145050A1 (en) * 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
US10183928B2 (en) * 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
CA3049136C (en) * 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2020035065A1 (zh) * 2018-08-17 2020-02-20 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物

Also Published As

Publication number Publication date
AU2021263541B2 (en) 2024-03-07
US11964968B2 (en) 2024-04-23
US20230312544A1 (en) 2023-10-05
BR112022021735A2 (pt) 2022-12-06
TW202206428A (zh) 2022-02-16
DOP2022000234A (es) 2022-11-30
AU2021263541A1 (en) 2022-11-24
WO2021222017A1 (en) 2021-11-04
US20210363140A1 (en) 2021-11-25
AR121914A1 (es) 2022-07-20
IL297551B1 (en) 2024-02-01
IL297551A (en) 2022-12-01
MX2022013482A (es) 2022-11-16
US11613533B2 (en) 2023-03-28
JP2023523315A (ja) 2023-06-02
CN115667253A (zh) 2023-01-31
CO2022016013A2 (es) 2022-11-18
EP4143184A1 (en) 2023-03-08
KR20230005301A (ko) 2023-01-09
CA3177080A1 (en) 2021-11-04
ECSP22083926A (es) 2022-11-30
CL2022003000A1 (es) 2023-06-23
IL297551B2 (en) 2024-06-01
JP7441972B2 (ja) 2024-03-01
TWI777509B (zh) 2022-09-11

Similar Documents

Publication Publication Date Title
PE20230780A1 (es) Compuestos utiles para inhibir la quinasa ret
PE20090772A1 (es) Derivados de bencimidazol
PE20220569A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos
ECSP099559A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
SV2006002103A (es) Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a
PE20081894A1 (es) Derivados de isoindolina 4'-o-sustituidos y composiciones que los comprenden y metodos para usarlos
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20080281A1 (es) COMPUESTOS CINAMIDA COMO INHIBIDORES DE LA SINTESIS DEL ß-AMILOIDE 40 Y 42
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
AR058139A1 (es) Microbiocidas y fungicidas y metodos de control
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20091673A1 (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilizacion
CL2008001669A1 (es) Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras.
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
PE20220016A1 (es) Inhibidores y metodos de uso de kcnt1
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
AR066063A1 (es) Derivados de triazol que son antagonistas de smo
RU2010101004A (ru) Новые микробиоциды